73 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 73 of 73 clinical reviews.
Evidence-based guide to alirocumab (Praluent) dosing in patients with renal impairment, including CKD stages 3-5, dialysis, and nephrotic syndrome. Covers pharmacokinetics, trial data, and clinical recommendations.
A clinician-grade review of alirocumab (Praluent) safety during pregnancy and breastfeeding, covering FDA labeling, animal data, placental transfer, and management of familial hypercholesterolemia in pregnant patients.
A physician-level review of alirocumab (Praluent) real-world evidence from registries, claims databases, and observational cohorts, including LDL-C reductions, MACE outcomes, adherence patterns, and how RWE compares with ODYSSEY OUTCOMES trial data.
An evidence-based review of how PCSK9, LDLR, APOE, and SLCO1B1 gene variants influence alirocumab (Praluent) efficacy, dosing, and clinical decision-making in hypercholesterolemia management.
A complete guide to Anthem (Elevance Health) Praluent coverage, prior-authorization criteria, step-therapy requirements, formulary tier, appeal strategy, and out-of-pocket cost options for alirocumab in 2024.
Find out whether Blue Cross Blue Shield covers Praluent (alirocumab), including prior authorization requirements, formulary tier placement, step therapy rules, and how to appeal a denial.
A breakdown of Cigna's coverage policy for Praluent (alirocumab), including prior-authorization criteria, step-therapy requirements, appeal rights, and real cost data for 2024 to 2025.
A guide to Humana coverage of Praluent (alirocumab), including formulary tiers, prior-authorization criteria, step therapy rules, and how to appeal a denial.
A complete guide to Kaiser Permanente coverage for alirocumab (Praluent), including prior authorization criteria, step therapy requirements, formulary tier, appeal strategies, and cost alternatives for FH and ASCVD patients.
A complete guide to Medicare Advantage coverage of Praluent (alirocumab): formulary tiers, prior authorization criteria, step therapy requirements, how to appeal denials, and patient assistance options.
State Medicaid coverage for Praluent (alirocumab) varies widely. Learn prior authorization criteria, formulary tiers, step therapy requirements, and how to appeal a denial.
A guide to TRICARE coverage of alirocumab (Praluent), including prior-authorization criteria, step-therapy requirements, formulary tier, appeal steps, and out-of-pocket cost options.
A detailed guide to UnitedHealthcare coverage of Praluent (alirocumab): formulary tier, prior-authorization criteria, step-therapy requirements, appeals, and cost-saving options, prepared by the HealthRX.com Editorial Team.
A complete clinical guide to obtaining a Praluent (alirocumab) prescription in California, including telehealth options, prior authorization requirements, lab work, and pharmacy logistics.
A complete guide to obtaining a Praluent (alirocumab) prescription in Colorado, including telehealth options, prior authorization steps, lab requirements, and pharmacy logistics.
A complete clinical guide to obtaining a Praluent (alirocumab) prescription in Washington DC: telehealth visits, required labs, prior authorization steps, pharmacy options, and what ODYSSEY OUTCOMES shows about cardiovascular risk reduction.
A complete guide to obtaining a Praluent (alirocumab) prescription in Hawaii, including telehealth options, prior authorization requirements, lab workup, and pharmacy logistics, prepared by the HealthRX.com Editorial Team.
A step-by-step clinical guide to obtaining a Praluent (alirocumab) prescription in Missouri, including telehealth options, prior authorization requirements, pharmacy access, and lab work.
A complete guide to obtaining a Praluent (alirocumab) prescription in New Mexico, including telehealth access, lab requirements, prior authorization, and pharmacy options.
A complete guide to obtaining a Praluent (alirocumab) prescription in Pennsylvania, including telehealth options, prior authorization requirements, pharmacy access, and clinical eligibility criteria.
A complete guide to obtaining a Praluent (alirocumab) prescription in Tennessee, including telehealth options, prior authorization requirements, lab work, and pharmacy access.
Evidence-based protocol for safely discontinuing alirocumab (Praluent), including LDL rebound data from ODYSSEY OUTCOMES, monitoring timelines, and when restarting PCSK9 inhibitor therapy is warranted.
Evidence-based guide to alirocumab (Praluent) dosing in adolescents aged 12, 17 with heterozygous familial hypercholesterolemia, including starting dose, titration, injection technique, and monitoring requirements.
A guide to monitoring alirocumab (Praluent) in adolescents aged 12, 17 with heterozygous familial hypercholesterolemia, covering lipid panels, growth, liver function, injection-site checks, and mental health screening.
A dosing and monitoring reference for alirocumab (Praluent) in adults, with FDA label guidance, ODYSSEY OUTCOMES trial data, and a clinician-discussion framework. Pending qualified medical review.
What Praluent costs in Minnesota in 2026, including cash prices, Medicaid coverage, insurance requirements, compounded alirocumab options, and manufacturer savings programs.
Current Praluent (alirocumab) pricing in New Hampshire for 2026. Covers retail cost, Medicaid status, insurance coverage, manufacturer savings cards, 503A compounding options, and telehealth access.
A clinical comparison of Praluent pricing against Repatha, Leqvio, bempedoic acid, and ezetimibe, with trial data, net cost estimates, and prescribing guidance for PCSK9-targeted therapy.
Evidence-based dosing guide for alirocumab (Praluent) in adults aged 50, 64, covering starting doses, titration, polypharmacy considerations, and ODYSSEY OUTCOMES trial data prepared by the HealthRX.com Editorial Team.
Complete clinical guide to alirocumab (Praluent) dosing in patients aged 18, 29, covering starting doses, titration, injection technique, safety in reproductive-age adults, and evidence from ODYSSEY trials.
Evidence-based guide to alirocumab (Praluent) dosing in patients with hepatic impairment, including pharmacokinetic considerations, clinical trial data, and monitoring recommendations.
Evidence-based guide to alirocumab (Praluent) food and supplement interactions. Covers statins, red yeast rice, omega-3s, grapefruit, vitamin D, and more with PubMed-cited clinical data.
Evidence-based guide to using alirocumab (Praluent) in transplant recipients, people living with HIV, chronic kidney disease, and other special populations where statin therapy is limited or insufficient.
A detailed look at how Praluent (alirocumab) is manufactured by Regeneron and Sanofi, its supply chain logistics, FDA shortage records, and what the patent war with Amgen meant for patient access.
Evidence-based guidance on handling a missed dose of Praluent (alirocumab), including timing thresholds, LDL rebound data, and how to get back on schedule safely.
A guide to monitoring alirocumab (Praluent) in adults aged 30, 49, covering lipid panels, injection-site reactions, liver enzymes, and cardiovascular endpoints based on ODYSSEY OUTCOMES and current ACC/AHA guidelines.
Evidence-based monitoring guide for alirocumab (Praluent) in adults aged 50 to 64, covering lipid panels, liver function, neurocognitive screening, injection-site assessment, and PCSK9 inhibitor safety labs.
A guide to alirocumab (Praluent) monitoring in young adults ages 18-29, covering lipid targets, injection-site checks, fertility considerations, and long-term follow-up protocols.
Evidence-based monitoring schedule for alirocumab (Praluent), including lipid panel timing, liver function tests, injection-site checks, and long-term follow-up intervals backed by ODYSSEY trial data and ACC/AHA guidelines.
A guide to alirocumab (Praluent) off-label uses, including peripheral artery disease, heart failure, kidney disease, and more. Each use rated by evidence strength with cited trials.
A clinical review of alirocumab (Praluent) patent expiration dates, biosimilar development, PCSK9 inhibitor market exclusivity, and when a generic or biosimilar version may become available.
A detailed clinical guide to alirocumab (Praluent) dosing in pediatric patients under age 12, covering FDA labeling status, trial evidence, weight-based considerations, monitoring requirements, and when to refer.
Evidence-based review of alirocumab (Praluent) safety in pediatric patients under 12, including FDA labeling status, off-label considerations, familial hypercholesterolemia management, and monitoring protocols.
A clinical deep-dive into alirocumab (Praluent) pharmacokinetics covering ADME, target-mediated drug disposition, dose-exposure relationships, and special population PK data with PubMed-cited evidence.
Full regulatory timeline for alirocumab (Praluent) across the US, EU, Canada, and UK, including approved indications, prescribing restrictions, and post-marketing requirements.
A guide to alirocumab safety for adults aged 30 to 49, covering injection-site reactions, myalgia, neurocognitive signals, drug interactions, pregnancy considerations, and long-term cardiovascular evidence from ODYSSEY OUTCOMES and related trials.
A clinical review of alirocumab (Praluent) safety for adults aged 50, 64, covering ODYSSEY trial data, injection-site reactions, myalgia, neurocognitive signals, polypharmacy considerations, and ACC/AHA guideline thresholds.
A guide to alirocumab (Praluent) safety in geriatric patients aged 65+, covering ODYSSEY OUTCOMES subgroup data, renal considerations, fall and fracture risk, drug interactions, and deprescribing thresholds.
A guide to alirocumab (Praluent) safety for young adults aged 18, 29, covering clinical trial data, injection-site reactions, fertility considerations, drug interactions, and monitoring protocols.
A detailed review of alirocumab (Praluent) safety signals, FDA regulatory actions, post-marketing surveillance data, and clinical trial safety findings from ODYSSEY OUTCOMES and other key studies.
Master the correct alirocumab (Praluent) self-injection technique with this guide covering pen use, site rotation, storage, and troubleshooting common errors.
A physician-level review of every clinically relevant drug-drug interaction for alirocumab (Praluent), including statins, warfarin, immunosuppressants, and more, with PubMed and FDA citations.
Find out exactly what Praluent (alirocumab) costs in Alabama in 2026, whether Alabama Medicaid covers it, how 503A compounding works, and the fastest way to lower your monthly bill.
A complete 2026 guide to alirocumab (Praluent) pricing in Alaska, including cash-pay costs, Alaska Medicaid coverage status, 503A compounding legality, insurance PA requirements, and the Regeneron/Sanofi savings card.
Praluent (alirocumab) costs $580/month list price in Arizona in 2026. Arizona Medicaid does not cover it. Compounded alirocumab via licensed 503A pharmacies may cost significantly less. This guide covers every cost-reduction path available to Arizona patients.
Praluent (alirocumab) carries a $580/month list price in Arkansas in 2026. This guide covers Arkansas Medicaid PA requirements, 503A compounded alirocumab, Regeneron/Sanofi savings cards, and telehealth access options.
Praluent (alirocumab) list price in California is $580/month in 2026. This guide covers Medi-Cal prior authorization, commercial insurance step therapy, the Regeneron/Sanofi savings card, and whether compounded alirocumab is legal in CA.
What does Praluent (alirocumab) actually cost in DC in 2026? Cash price, DC Medicaid PA requirements, insurance coverage, manufacturer savings cards, and compounded alirocumab options explained with clinical context.
A complete 2026 guide to alirocumab (Praluent) pricing in Indiana, including cash-pay costs, Indiana Medicaid coverage status, compounded alirocumab legality, insurance prior-authorization tips, and manufacturer savings programs.
How much does Praluent (alirocumab) cost in Maryland in 2026? Get cash prices, Medicaid PA requirements, savings card details, and compounded alirocumab options.
Showing the first 60 matches. Use search or filters to narrow the library.